A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Patients With Atopic Dermatitis

NCT07015762 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: IBI3002
DRUG: Placebo

Sponsor

The First Affiliated Hospital of Soochow University

Collaborators

[object Object]